NT5C1A and inclusion body myositis: As expected, independent of anti‐NT5C1A antibody status, patients with IBM were significantly older (59.4 ± 8.7 vs. 53.5 ± 15.9 years old; P < 0.01) and male 59% as compared to 41% in the non‐IBM cohort (P < 0.01, Table S1).